Nicox SA
Company Profile
Business description
Nicox SA is an international ophthalmology company developing solutions to help maintain vision and improve ocular health. Its program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.
Contact
Rue Evariste Galois
Emerald Square, Batiment C
Sundesk Sophia Antipolis
Biot06410
FRAT: +33 497245300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.00 | 2.50 | 0.03% |
| CAC 40 | 8,274.64 | 33.40 | 0.41% |
| DAX 40 | 24,041.62 | 339.84 | -1.39% |
| Dow JONES (US) | 47,457.22 | 797.60 | -1.65% |
| FTSE 100 | 9,838.00 | 73.42 | -0.74% |
| HKSE | 26,680.12 | 392.91 | -1.45% |
| NASDAQ | 22,870.36 | 536.10 | -2.29% |
| Nikkei 225 | 50,375.84 | 905.99 | -1.77% |
| NZX 50 Index | 13,464.46 | 207.27 | -1.52% |
| S&P 500 | 6,737.49 | 113.43 | -1.66% |
| S&P/ASX 200 | 8,634.50 | 8.90 | 0.10% |
| SSE Composite Index | 4,016.77 | 12.74 | -0.32% |